Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MBF-118 in Crohn's Disease Patients with Stenosis
NCT05940558Phase 2Completed
- Sponsor
- Medibiofarma
- Start
- Apr 2023
- Primary completion
- Sep 2024
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of MBF-118 in Crohn's disease (2 arms), sponsored by Medibiofarma. Primary endpoint: Number of Adverse events at 12 weeks. Started Apr 2023; status: completed.
02
Drugs
MBF-118
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT05940558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05940558.